Participated · Equity · Jul 2026

Founded in 2014 and headquartered in Louvain-la-Neuve, e-peas develops and markets ultra-low-power semiconductor technology that enables devices to operate from ambient energy sources such as light, RF, vibration, and heat. Its product portfolio includes energy-harvesting power management ICs, microcontrollers, and sensor solutions backed by about 15 years of research and patented IP. The company says its solutions power high-volume applications including solar-powered remote controls, HVAC systems, cameras, and smart tracking devices for global customers. e-peas aims to extend battery lifespans and eliminate battery replacements for industrial and IoT device designers. Financially, the company has raised multiple rounds including €8 million in 2020, €17.5 million in March 2024, and the recent €19.2 million round to support commercial scaling and international expansion. The firm also maintains offices in Switzerland and the USA.

Participated · Series A · Apr 2026

NeuroClues offers a portable, CE‑marked Class IIa medical device that records high‑speed infrared eye movements and applies proprietary AI algorithms to generate objective neurological biomarkers within minutes. The system is intended for use in hospitals, private neurology practices, and research centers and replaces subjective observational assessments with quantified data that can integrate into clinical workflows. After securing CE certification in early 2025, the company deployed more than 30 devices across seven European countries, including France, Belgium, Italy, Germany, Switzerland, the Netherlands, and the UK. NeuroClues is building clinical partnerships—such as integration into cohorts at the Paris Brain Institute—and is participating in a large-scale study to develop a 25,000-participant normative oculomotor biomarker database. The company aims to enable earlier and more precise identification of neurological conditions including Parkinson’s disease, Alzheimer’s disease, and concussion‑related impairments. Financially, NeuroClues has raised €25 million in total capital to date, including the recent €10 million Series A and additional non‑dilutive funding, and is expanding its commercial organization to support wider European rollout.

Participated · Seed · Mar 2026

Vertical Compute is a Belgian semiconductor startup engineering chiplets in which vertical memory stacks are integrated directly on top of compute logic during 300 mm wafer fabrication. This 3D architecture restructures on-chip data flow and addresses the longstanding “memory wall,” cutting latency and energy use compared with traditional 2D memory layouts. The company has already produced its first test chip demonstrating the concept. With a headcount of 25, Vertical Compute now plans to shift from validation to the commercial rollout of its chiplets for emerging AI platforms. Financially, the startup has secured €57 million to date, including a €20 million round in 2022 and the latest €37 million raise. No revenue figures have been disclosed, but the fresh capital provides runway for scaling manufacturing and bringing its products to market.

Participated · Seed · Jan 2026

Enodia Therapeutics is building a small-molecule drug discovery platform that selectively modulates the SEC61 translocon, enabling degradation of secreted and membrane proteins before they leave the endoplasmic reticulum. The approach blends a tailored library of signal-peptide cell lines, proteomics-based secretome analysis and machine-learning models to achieve unprecedented selectivity in targeted protein degradation. Originating from research at the Institut Pasteur and incubated by Argobio Studio, the company is initially pursuing inflammatory and autoimmune disease programs while exploring applications in oncology and viral infections. Management intends to advance the lead program to preclinical candidate selection within the next twelve months, marking a key value inflection point. The platform leverages several families of well-characterized inhibitors, offering the potential to unlock previously undruggable targets. Enodia’s strategy emphasizes repeated translation of complex SEC61 biology into differentiated drug candidates and broad partnering potential. The recent seed financing provides the capital to validate the platform and expand the early pipeline. No commercial revenue or clinical-stage assets have been disclosed to date.

Participated · Seed · Dec 2025

AILOS Robotics is a Brussels-based spin-off from the Vrije Universiteit Brussel and its BruBotics research centre that focuses on robotic actuation. After a decade of research supported by VLAIO and Innoviris, the team has commercialised its patented R2poweR gearbox, which blends quasi-direct drive agility with industry-leading torque density. The architecture enables lighter, quieter, more energy-efficient robots capable of safe human interaction, and is designed for cost-effective, scalable production suited to high-volume manufacturing. Having validated its minimum viable product, the company is now transitioning from lab to factory and engaging robot manufacturers for pilot integrations. Near-term plans include scaling manufacturing capacity and solidifying supply-chain partnerships to support Europe’s humanoid and collaborative robotics sectors. Financially, AILOS has secured a €3.5 million seed round to fund industrialisation; no revenue or deployment metrics have yet been disclosed.